InsidersTradesSigma
Follow the C4 Therapeutics, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, C4 Therapeutics, Inc. has recorded 180 public disclosures. Market capitalisation: €473.6m. The latest transaction was filed on 14 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Anderson Kenneth Carl. Every trade is free.
180
Insider Decl.
n/a
Thresholds
€107,167
2 ops.
Buy Volume
€4m
18 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate C4 Therapeutics, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$13.33.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 August 2026
Declarations180 total
4,139 shares@ US$4.25340.0035% mcap11.3% of flowCommonSEC144:0001950047-26-008193
15,000 shares@ US$4.07150.012% mcap44.4% of flowCommonSEC144:0001950047-26-008065
19,519 shares@ US$3.92850.015% mcap100.0% of flowCommonSEC144:0001950047-26-008039
15,325 shares0Common StockSEC:0001470831-26-000705:0
7,397 shares@ US$4.060.0063% mcap30.3% of flowCommon StockSEC:0001470831-26-000705:1
2,650 sharesCommon StockSEC:0001470831-26-000688:0
1,070 shares@ US$2.110.0004% mcap1.1% of flowCommon StockSEC:0001470831-26-000504:0
4,259 shares@ US$2.705.4% of flowCommon StockSEC:0001470831-26-000346:0
5,370 shares@ US$2.708.6% of flowCommon StockSEC:0001470831-26-000345:0
200,000 shares0Common StockSEC:0001470831-26-000180:0
240,000 shares0Common StockSEC:0001470831-26-000179:0
200,000 shares0Common StockSEC:0001470831-26-000178:0
700,000 shares0Common StockSEC:0001470831-26-000177:0
240,000 shares0Common StockSEC:0001470831-26-000176:0
240,000 shares0Common StockSEC:0001470831-26-000175:0
56,980 shares0Common StockSEC:0001470831-26-000174:0
10,000 shares@ US$2.2231.7% of flowCommon StockSEC:0001470831-26-000045:0
5,958 shares@ US$1.935.2% of flowCommon StockSEC:0001470831-26-000009:0
7,513 shares@ US$1.936.8% of flowCommon StockSEC:0001470831-26-000008:0
19,200 shares0Common StockSEC:0001193125-25-258664:0
5,349 shares@ US$2.155.5% of flowCommon StockSEC:0001470831-25-000250:0
6,740 shares@ US$2.157.3% of flowCommon StockSEC:0001470831-25-000249:0
6,250 shares0Common StockSEC:0001470831-25-000223:0
15,325 shares0Common StockSEC:0001662579-25-000057:0
7,382 shares@ US$1.9930.5% of flowCommon StockSEC:0001662579-25-000055:0
25 of 180 declarations
关于 C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (NASDAQ: CCCC) 是一家在美国上市的生物制药公司，总部位于美国马萨诸塞州沃特敦，成立于2015年。对于投资者而言，它符合临床阶段生物技术公司的特征，专注于差异化的科学平台而非商业化的产品组合。公司的核心使命是利用靶向蛋白降解 (TPD) 技术，这种方法旨在消除致病蛋白，而非仅仅抑制它们。([c4therapeutics.com](https://c4therapeutics.com/our-company/?utm_source=openai)) C4 Therapeutics 专有的 TORPEDO® 平台旨在高效发现和优化小分子降解剂，利用人体天然的蛋白质回收机制。管理层将该平台视为解决难治靶点、克服耐药机制以及开发具有高效力和特异性的口服药物的潜在途径。在竞争方面，C4T 活跃于新兴的蛋白质降解领域，在该领域，科学可信度、转化执行力和合作质量与核心临床资产同等重要。([sec.gov](https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm?utm_source=openai)) 公司最重要的内部项目集中在肿瘤学领域。Cemsidomide 是一种 IKZF1/3 降解剂，正在推进用于复发/难治性多发性骨髓瘤，包括2026年后期开发活动。CFT1946 靶向实体瘤中的 BRAF V600 突变，而 CFT8919 是一种 EGFR L858R 降解剂，正在开发用于非小细胞肺癌，初步工作通过合作伙伴在大中华区进行。除了这些主要项目，C4 Therapeutics 继续探索炎症、神经炎症和神经退行性疾病领域的额外发现工作，这随着时间的推移拓宽了平台叙事，超越了肿瘤学领域。([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) 从地理上看，公司仍以美国为中心，研发和公司运营位于马萨诸塞州沃特敦，同时利用全球合作网络。与罗氏、百健、默克集团和辉瑞的战略合作表明，C4T 利用合作既验证其科学性，又帮助资助开发。这种模式可以减少一些独立的开发负担，但也意味着未来的价值创造在很大程度上取决于合作伙伴的执行和里程碑的实现。([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-transformation-strategic-collaboration/?utm_source=openai)) 最近的发展强化了作为催化剂驱动型生物技术故事的投资案例。在2025-2026年，C4 Therapeutics 报告称 cemsidomide 已进入用于四线或更晚期多发性骨髓瘤的 MOMENTUM 2期临床试验，预计与 elranatamab 的联合研究将于2026年第二季度开始。公司还强调，由百健设计并交付的第二种降解剂已进入自身免疫疾病的临床开发阶段，其2025年末更新披露的现金、现金等价物和有价证券为297.1 million美元，支持其运营至2028年末。([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
